Skip to content

AI Prediction Model and Risk Stratification for Lung Metastasis in Colorectal Cancer

Development and Validation of an Artificial Intelligence Prediction Model and a Survival Risk Stratification for Lung Metastasis in Colorectal Cancer From Highly Imbalanced Data

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05816902
Enrollment
2779
Registered
2023-04-18
Start date
2016-01-01
Completion date
2020-12-31
Last updated
2023-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer, Lung Metastases

Brief summary

Background: To assist clinicians with diagnosis and optimal treatment decision-making, we attempted to develop and validate an artificial intelligence prediction model for lung metastasis (LM) in colorectal cancer (CRC) patients. Method: The clinicopathological characteristics of 46037 CRC patients from the Surveillance, Epidemiology, and End Results (SEER) database and 2779 CRC patients from a multi-center external validation set were collected retrospectively. After feature selection by univariate and multivariate analyses, six machine learning (ML) models, including logistic regression, K-nearest neighbor, support vector machine, decision tree, random forest, and balanced random forest (BRF), were developed and validated for the LM prediction. The optimization model with best performance was compared to the clinical predictor. In addition, stratified LM patients by risk score were utilized for survival analysis.

Interventions

OTHERThe location of the patient's treatment

The location of the patient's treatment

Sponsors

The Second Affiliated Hospital of Harbin Medical University
CollaboratorOTHER
Peking Union Medical College
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL

Inclusion criteria

* patients with pathologic confirmation of a primary CRC diagnosis

Exclusion criteria

* (1) patients with multiple primary cancers or other malignancies; (2) patients identified via autopsy or death certificate; and (3) patients with uncertain clinical data values

Design outcomes

Primary

MeasureTime frameDescription
lung metastasisthrough study completion, an average of 3 monthdiagnosed with lung metastasis

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026